The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Dapagliflozin and Neuro-Nutrition: A Pragmatic Approach to Manage Diabetic Peripheral Neuropathy


Affiliations
1 President-Medical & Regulatory Affairs, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, Mumbai, India
2 Deputy General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, India
3 Assistant General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, India
     

   Subscribe/Renew Journal


Diabetic peripheral neuropathy (DPN) is the most prevalent microvascular complication of diabetes mellitus. DPN results from a complex interaction of factors including hyperglycemia, glucotoxicity, increased intracellular glucose concentration-induced mitochondrial dysfunction, oxidative stress, etc. A multifaceted approach is warranted for the clinical treatment of DPN. Combination therapy of an antidiabetic agent along with neuro-nutrition aimed at addressing the pathogenic features of neuropathy can be a potential treatment option for effective management of DPN.

Keywords

Type 2 Diabetes (T2DM), Diabetic Peripheral Neuropathy (DPN), Dapagliflozin, Neuro-Nutrition, B-Group Vitamins, Neuroprotection.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Zimmet PZ, Diabetes and its Drivers: the Largest Epidemic in Human History? Clin. Diabetes Endocrinol;p.3 (1), 1–8.

  • IDF. Diabetes Facts & Figures, the IDF Diabetes Atlas Ninth Edition 2019.

  • Bromberg MB, An Approach to the Evaluation of Peripheral Neuropathies. Seminars in Neurology, 25. p. 153-159.

  • Maladkar M, Tekchandani C, Dave U; Post-Marketing Surveillance of Fixed Dose Combination of Methylcobalamin, Alpha Lipoic Acid, Folic Acid, Biotin, Benfotiamine & Vitamin B6-Nutripathy for the Management of Peripheral Neuropathy. Journal of Diabetes Mellitus 4. p. 124-132.

  • Pugazhenthi S, Qin L, Reddy PH; Common Neurodegenerative Pathways in Obesity, Diabetes, and Alzheimer’s Disease. Biochim. Biophys. Acta Mol. Basis Dis. 1863 (5). p.1037–1045.

  • Boulton AJ, Diabetic Neuropathy and Foot Complications. Handb. Clin. Neurol 126. p.97–107. doi:10.1016/B978-0-444-53480-4.00008-4

  • Kandeel M. The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis. Front Pharmacol. 2022 Jul 11;13 p 926717.

  • Sa-Nguanmoo P, Tanajak P, Kerdphoo S, et al. SGLT2-inhibitor and DPP-4 Inhibitor Improve Brain Function via Attenuating Mitochondrial Dysfunction, Insulin Resistance, Inflammation, and Apoptosis in HFD-Induced Obese Rats. Toxicol. Appl. Pharmacol. 333, p 43–50.

  • Duby JJ, Campbell RK, Setter SM, et al. (2004) Diabetic neuropathy: an intensive review. Am J Heal Pharm 61:160–176.

  • Cameron NE, Eaton SEM, Cotter MA, et al. (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44, p 1973–1988.

  • Obrosova IG (2002) How does glucose generate oxidative stress in peripheral nerve? Int Rev Neurobiol 50, p 3–35.

  • World Health Organization (2006) Neurological Disorders: Public Health Challenges. World Health Organization, p 111-174.

  • Kumar N. Nutritional Neuropathies. Neurologic Clinics, 25, p 209-255.

  • Luo J.J, Sivaraaman K, Nouh A. et al. Elevated Plasma Level of Homocysteine Is an Independent Risk Factor for Peripheral Neuropathy. British Journal of Medicine & Medical Research, 4, p 161-169.

  • Caiqin W, Hui P, Wenli W. et al. Effect Of Dapagliflozin Combined With Mecobalamin On Blood Glucose Concentration And Serum MDA, SOD, And Cox-2 In Patients With Type 2 Diabetes Mellitus Complicated With Peripheral Neuropathy. Acta Medica Mediterranea, 35, p 2211.

  • Wiciński M, Wódkiewicz E, Górski K, et al. Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury. Pharmaceuticals 2020 Nov 11;13(11) p 379. doi: 10.3390/ph13110379.

  • Sun Y, Lai MS. Lu CJ. Effectiveness of Vitamin B12 on Diabetic Neuropathy: Systematic Review of Clinical Controlled Trials. Acta Neurologica Taiwanica, 2005 Jun;14(2). p 48-54.

  • Stracke H, Lindemann A, Federlin K. A Benfotiamine-Vitamin B Combination in Treatment of Diabetic Polyneuropathy. Experimental and Clinical Endocrinology & Diabetes, 1996;104(4). p 311-6. doi: 10.1055/s-0029-1211460.


Abstract Views: 56

PDF Views: 0




  • Dapagliflozin and Neuro-Nutrition: A Pragmatic Approach to Manage Diabetic Peripheral Neuropathy

Abstract Views: 56  |  PDF Views: 0

Authors

Manish Maladkar
President-Medical & Regulatory Affairs, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, Mumbai, India
Shrikant Patil
Deputy General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, India
Ashok Yadav
Assistant General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, India

Abstract


Diabetic peripheral neuropathy (DPN) is the most prevalent microvascular complication of diabetes mellitus. DPN results from a complex interaction of factors including hyperglycemia, glucotoxicity, increased intracellular glucose concentration-induced mitochondrial dysfunction, oxidative stress, etc. A multifaceted approach is warranted for the clinical treatment of DPN. Combination therapy of an antidiabetic agent along with neuro-nutrition aimed at addressing the pathogenic features of neuropathy can be a potential treatment option for effective management of DPN.

Keywords


Type 2 Diabetes (T2DM), Diabetic Peripheral Neuropathy (DPN), Dapagliflozin, Neuro-Nutrition, B-Group Vitamins, Neuroprotection.

References